Zacks Research Has Positive Estimate for Zoetis Q1 Earnings

Zoetis Inc. (NYSE:ZTS) – Analysts at Zacks Research raised their Q1 2026 earnings estimates for Zoetis in a research note issued to investors on Tuesday, December 3rd. Zacks Research analyst E. Bagri now expects that the company will earn $1.63 per share for the quarter, up from their prior estimate of $1.62. The consensus estimate for Zoetis’ current full-year earnings is $5.90 per share. Zacks Research also issued estimates for Zoetis’ Q2 2026 earnings at $1.77 EPS and FY2026 earnings at $6.94 EPS.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, beating the consensus estimate of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The firm had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.29 billion. During the same period last year, the business posted $1.36 EPS. Zoetis’s quarterly revenue was up 11.6% on a year-over-year basis.

Several other equities research analysts have also issued reports on ZTS. JPMorgan Chase & Co. increased their price objective on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. Leerink Partners initiated coverage on Zoetis in a research note on Monday, December 2nd. They set an “outperform” rating and a $215.00 target price for the company. Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. BTIG Research upped their target price on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Finally, Piper Sandler upped their price target on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a report on Wednesday, August 14th. Ten equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $219.00.

Zoetis Stock Up 1.0 %

ZTS opened at $176.46 on Friday. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27. The stock has a market capitalization of $79.61 billion, a price-to-earnings ratio of 33.17, a price-to-earnings-growth ratio of 2.86 and a beta of 0.89. Zoetis has a 12 month low of $144.80 and a 12 month high of $201.92. The business has a 50-day moving average of $182.07 and a two-hundred day moving average of $181.00.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st were issued a dividend of $0.432 per share. This represents a $1.73 dividend on an annualized basis and a yield of 0.98%. The ex-dividend date of this dividend was Thursday, October 31st. Zoetis’s payout ratio is currently 32.52%.

Institutional Investors Weigh In On Zoetis

Several large investors have recently modified their holdings of ZTS. Simplify Asset Management Inc. acquired a new position in shares of Zoetis in the 3rd quarter valued at about $11,684,000. Bank Pictet & Cie Asia Ltd. grew its position in Zoetis by 41.0% in the second quarter. Bank Pictet & Cie Asia Ltd. now owns 37,500 shares of the company’s stock worth $6,501,000 after acquiring an additional 10,900 shares in the last quarter. B&L Asset Management LLC acquired a new position in shares of Zoetis during the 3rd quarter worth $563,000. Swedbank AB raised its holdings in shares of Zoetis by 56.2% during the 2nd quarter. Swedbank AB now owns 1,946,277 shares of the company’s stock valued at $337,407,000 after purchasing an additional 700,398 shares in the last quarter. Finally, Dai ichi Life Insurance Company Ltd lifted its holdings in Zoetis by 16.3% in the 3rd quarter. Dai ichi Life Insurance Company Ltd now owns 74,499 shares of the company’s stock worth $14,556,000 after purchasing an additional 10,427 shares during the last quarter. 92.80% of the stock is owned by institutional investors.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.